Skip to main content

Artery Disease in Psoriasis Tied to LOX-1 Levels

Soluble lectinlike oxidized low-density lipoprotein receptor-1 (sLOX-1) levels are likely elevated in patients with psoriasis and associated with disease severity, according to the findings of a recent study.

Psoriasis is known to be associated with accelerated noncalcified coronary burden (NCB) and accelerated lipoprotein oxidation. “A transmembrane scavenger receptor for these oxidized modified lipoproteins is LOX-1, which has been reported to be associated with coronary artery disease,” the researchers said. “It is unknown whether this receptor is associated with coronary artery disease in psoriasis.”
Related content

Exploring Psoriasis and Cardiovascular Comorbidity
Does Body Weight Affect Psoriasis Risk?

Findings from a recent study showed the potential role of lectinlike oxidized low-density lipoprotein receptor-1 (LOX-1) in noncalcified coronary burden among patients with psoriasis.

To examine this potential association further, the researchers assessed the association between sLOX-1 and NCB among 175 patients with psoriasis referred to outpatient dermatology practices between January 1, 2013 and October 1, 2017. In addition, 138 patients with psoriasis were followed up at 1 year. Circulating sLOX-1 levels were measured using an enzyme-linked immunosorbent assay, and coronary computed tomography angiography scans were used to quantify NCB in all 3 major epicardial coronary arteries.

Among the 175 patients, the researchers found relatively low median cardiovascular risk by Framingham risk score and a mean body mass index suggestive of overweight profiles.

Patients with psoriasis had elevated sLOX-1 levels compared with age- and sex-matched controls, the researchers said. These levels were associated with Psoriasis Area and Severity Index (PASI) score.

In addition, the researchers found sLOX-1 was associated with NCB independent of hyperlipidemia status and was persistent after adjusting for traditional cardiovascular risk factors, statin use, and biologic psoriasis treatment.

At 1 year, clinical improvement in PASI was associated with reduction in sLOX-1, which was associated with a reduction in NCB, the researchers said. This finding suggests a potential role of this lipid protein in inflammatory atherogenesis in psoriasis, they noted.

These findings suggest that reductions of sLOX-1 level at 1 year are associated with improvements in patients with psoriasis,” the researchers concluded.


Dey AK, Gaddipati R, Elnabawi YA, et al. Association between soluble lectinlike oxidized low-density lipoprotein receptor-1 and coronary artery disease in psoriasis [published online November 20, 2019].  JAMA Dermatol. doi:10.1001/jamadermatol.2019.3595


Back to Top